NEWARK/NEW YORK
mtanenbaum@tktrial.com
(973) 820-0019
Linkedin
Download PDF
vCard

Michael A. Tanenbaum

Co-Chair

Mr. Tanenbaum’s practice focuses on product liability, pharmaceutical liability, commercial litigation and environmental and toxic tort litigation. He handles, from inception through appeal, complex commercial and product liability litigation and has served as lead MDL Counsel, National Product Liability Counsel and Resolution Counsel for pharmaceutical, consumer products, building products and chemical companies, as well as for a global industrial contractor and power equipment manufacturer.

For several decades Mr. Tanenbaum has provided litigation counseling and litigation management services to numerous leading corporations including Boston Scientific, Bristol-Myers Squibb Company, ViacomCBS, ExxonMobil Corporation, General Electric Company, Clairol, Inc., Hoover Treated Wood Products and Foster Wheeler, LLC.

Prior to founding Tanenbaum Keale LLP, Mr. Tanenbaum was a partner with McCarter & English LLP and Sedgwick LLP where he also served as chair of the firm from 2007 to 2015.

Mr. Tanenbaum is admitted to practice law before the courts in New York, New Jersey and Florida and the United States Supreme Court.

Mr. Tanenbaum serves on the Board of Directors for the New Jersey Performing Arts Center and is a member of the Board’s Executive Committee and Chair of the Audit Committee. He is a past Chair of the Overlook Foundation.

He is the recipient of InsideCounsel Magazine’s 2013 James M. Strother Award, which recognizes a law firm managing partner whose courage, unyielding vision, integrity, conviction and authenticity has carved a groundbreaking path and laid a new foundation to accelerate the economic empowerment of attorneys of color and women. Mr. Tanenbaum also has been recognized as a Local Litigation Star by Benchmark Litigation and in Best Lawyers in America every year since 2006.

Mr. Tanenbaum is a member of the New Jersey, New York and Florida State Bars and former chair of the Federation of Defense and Corporate Counsel’s Drug, Device and Biotechnology Section.

  • Co-author, "As Zantac Litigation Accelerates, MDL Data Collection Is Key," Law360, April 2020
  • Co-author, "How Cos. Can Prepare For Heartburn Drug Cancer Claims," Law360, February 2020
  • Presenter, “Post-Settlement Considerations: The Devil is in the Details,” Mass Tort Judicial Forum, HB Litigation Conferences, April 2018
  • Author, “Boutique Firms Gain Momentum in the Legal Industry,” The Mid-Market Report, March 2018
  • Co-author, “Chapter 25 – Privilege in a Global Product Economy,” Product Liability Litigation: Current Law, Strategies and Best Practices, Practising Law Institute Treatise, 2nd Edition (October 2009)
  • “The Changing World of Causation,” 2008 Federation of Defense and Corporate Counsel Winter Meeting (February 2008)
  • “Current Legal Trends in New York Asbestos Litigation,” American Chemistry Council (Tort Litigation Group) (November 2005)
  • Mr. Tanenbaum has also presented at the IADC Annual Meeting on the economics of case management and served as a faculty member at the Georgetown Mass Tort Institute.
  • J.D. (1981) Boston University School of Law, cum laude
  • A.B. (1978) Princeton University, magna cum laude